Elivaldogene autotemcel
| Clinical data | |
|---|---|
| Trade names | Skysona |
| Other names | Lenti-D, eli-cel |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank | |
| UNII | |
| KEGG | |
Elivaldogene autotemcel, sold under the brand name Skysona, is a gene therapy used to treat cerebral adrenoleukodystrophy (CALD). It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in May 2018.
Elivaldogene autotemcel is made specifically for each recipient, using the recipient's hematopoietic stem cells.
It was approved for medical use by the U.S. Food and Drug Administration in September 2022.